ScreenerHero

RADX Radiopharm Theranostics Limited

NAS · US · Healthcare · Biotechnology · radiopharmtheranostics.com
1.150USD-2.54%Mkt Cap: 16.78M $P/E: —

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The compa…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap16.78M USD
Enterprise Value10.56M USD
Revenue (TTM)12.87M USD
Gross Profit39.28K USD
Net Income (TTM)-38.34M USD
Revenue/Share1.20 USD
Last Price1.150 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.51
PEG—
EV/EBITDA-0.21
EV/Revenue0.82
P/S1.34
P/B0.81
EPS (TTM)-3.64
EPS (Forward)-2.32
52W Range
1.0001% of range16.25
52W High16.25 USD
52W Low1.000 USD
Profitability
Gross Margin1.08%
Oper. Margin-400.35%
EBITDA Margin0.00%
Profit Margin-1055.27%
ROE-85.60%
ROA-44.34%
Growth
Revenue Growth-36.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.78M USD
CapEx (TTM)—
FCF Margin-242.07%
FCF Yield-185.59%
Net Debt-4.14M USD
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity—
Current Ratio1.16
Quick Ratio1.14
Book Value/Sh1.46 USD
Cash/Share0.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.04 USD
Upside (mean)+1381.4%
Target Range12.47 USD – 30.09 USD
12.47+1381.4% to mean30.09
# Analysts6
Ownership
Shares Out.14.59M
Float11.96M
Insiders0.00%
Institutions0.74%
Short Interest
Short Ratio0.6d
Short % Float0.33%
Short % Out.0.29%
Shares Short42.22K
Short (prev mo.)27.00K
Technical
SMA 502.273 (-49.4%)
SMA 2004.068 (-71.7%)
Beta0.86
S&P 52W Chg15.78%
Avg Vol (30d)63.69K
Avg Vol (10d)50.95K
Technical Indicators
RSI (14)23.3
MACD-0.2844
MACD Signal-0.2787
MACD Hist.-0.0057
BB Upper2.077 USD
BB Middle1.594 USD
BB Lower1.111 USD
BB Width60.60%
ATR (14)0.2171 USD
Vol Ratio (20d)0.66x